Tendon, ligament and musculoskeletal soft-tissue injury — compounds assessed
The 2 compounds the Institute assesses in tendon, ligament and musculoskeletal soft-tissue injury.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Synthetic pentadecapeptide derived from a gastric juice protein sequence0 contributing trialsfull monograph
No randomised controlled human trial identified — The tendon and ligament claims that dominate discussion of this compound rest entirely on rodent models. There is no human trial.
Very low -
No randomised controlled human trial identified — Preclinical rodent and equine work only.
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.